The European Medicines Agency issued draft guidance proposing accelerated trial approvals during public health emergencies, urging sponsors to prioritize well‑designed, multi‑site clinical trials and to engage the EMA’s Emergency Task Force (ETF). The draft aims to prevent fragmented compassionate use programs and small isolated studies that dilute evidence, while preserving participant safety and data integrity. Proposed flexibilities include faster authorizations for trials addressing the emergency and mechanisms to transfer participants between sites when needed. The guidance stresses that regulatory flexibility must be balanced with robust trial design to ensure meaningful evidence generation, reflecting lessons from the COVID‑19 pandemic. Sponsors and trial networks should anticipate streamlined interactions with the EMA ETF and adapt operational plans to meet the draft’s emphasis on inclusivity and statistical rigor.